Abstract 1604P
Background
In nonclinical studies, prostate-specific membrane antigen (PSMA)-targeted RLT plus androgen antagonist had synergistic cytotoxic effects on prostate cancer (PCa) cells.
Methods
ARROW recruited mCRPC pts (≥18 years) who were to receive enza after progression on abi. mCRPC was confirmed by histopathology and PSMA-PET avidity (piflufolastat F 18), while RECIST 1.1 and Prostate Cancer Working Group 3 (PCWG3) criteria were applied. Pts were randomized 2:1 to either enza (160 mg QD) plus 1095 (100 mCi dose, then up to 4 cycles ≥8 weeks apart, as determined by dosimetry and dose-limiting events) or enza. The primary endpoint was prostate-specific antigen response rate (PSA RR): first occurrence of ≥50% decline in PSA from baseline, confirmed by a second measurement ≥3 weeks later. Secondary endpoints included radiographic-progression–free survival (rPFS), overall response rate (ORR), landmark overall survival (OS), PSA progression (PCWG3 criteria), duration of response, & safety. The primary endpoint assumed a RR of 59% for 1095+enza and 30% for enza. With 2:1 randomization and anticipated 15% dropout, ≥102 pts were needed to provide 80% power for a 2-sided χ2 test (α=0.05). A 2-sided Cochran-Mantel-Haenszel χ2 test stratified by risk category was used for the primary endpoint.
Results
Of 177 screened pts, 120 were randomized to enza+1095 (n=80) or enza (n=40). Patient characteristics in both arms were similar at baseline. PSA RR was 62.86% for enza+1095 pts vs 31.25% for enza pts (p=0.0025). Median rPFS was 14.0 months (95% CI: 8.64-18.20) for enza+1095 vs 11.5 months (2.79-18.43) for enza (p=0.1032). Incidence of TEAEs of grade ≥3 was 65.8% (enza+1095) vs 41.0% (enza). Most frequent TEAEs for enza+1095 vs enza, respectively, were fatigue (75.0%, 53.8%), nausea (59.2%, 33.3%), and decreased appetite (48.7, 17.9%).
Conclusions
There was statistically and clinically significant improvement in PSA RR for enza+1095 vs enza alone.
Clinical trial identification
NCT03939689.
Editorial acknowledgement
Writing and editorial support were provided by Vincent DiPippo of Progenics Pharmaceuticals, a Lantheus company, and Laurie Thomas of Winfield Consulting.
Legal entity responsible for the study
Lantheus Lantheus.
Funding
Lantheus.
Disclosure
E.Y. Yu: Other, Personal, Speaker, Consultant, Advisor: Jansen, Merck, AAA Novartis, Bayer, Aadi Bioscience, Oncternal, BMS, Loxo, Lantheus; Non-Financial Interests, Institutional, Speaker, Consultant, Advisor: Dendreon, Merck, Seagen, Blue Earth, Bayer, Lantheus, Tyra, Oncternal. V. Narayan: Other, Personal, Speaker, Consultant, Advisor: Ferring Pharmaceutials, Ciox; Other, Institutional, Research Funding: Ferring; Financial Interests, Institutional, Research Funding: Ciox. G. Esposito: Other, Personal, Speaker’s Bureau: Lantheus. R. Szmulewitz: Other, Personal, Speaker, Consultant, Advisor: Astellas Pharma, Pfizer/Astellas, AstraZeneca, AbbVie, Exelixis, Merck, Amgen, Janssen Oncology, Sanofi, Astellas Pharma, Pfizer; Other, Institutional, Research Funding: AbbVie, Astellas Pharma, Macrogenics, Janssen Oncology, Plexxikon, Harpoon Therapeutics, Merck, Novartis; Financial Interests, Personal, Other, Patent licensed to Corcept Therapeutics: University of Chicago. Y. Lu: Other, Institutional, Research Grant: Lantheus; Other, Personal, Local PI: Lantheus. M. Lilly: Other, Personal, Local PI: Lantheus; Other, Institutional, Research Funding: Lantheus. J. Calais: Other, Personal, Advisory Role: Amgen, Advanced Accelerator Applications, Astellas, Bayer, Blue Earth Diagnostics, Curium Pharma, DS Pharma, Fibrogen, GE Healthcare, Isoray, IBA Radiopharma, Janssen Pharmaceuticals, Monrol, Lightpoint Medical, Lantheus, Novartis, Pfizer, Point Biopharma, Progenics, Radiomedix, Sanofi, Siemens-Varian, SOFIE, Telix Pharmaceuticals; Other, Institutional, Research Grant: Lantheus, Novartis, POINT Biopharma. G. Bratslavsky: Financial Interests, Personal, Other, Salary, stocks and ownership: Avicella; Financial Interests, Personal, Other, Salary and stocks: Aptametrix; Financial Interests, Personal, Ownership Interest: Ilgen, Taurus; Financial Interests, Institutional, Local PI: Ferring Pharmaceuticals, Curium US LLC, QED Therapeutics, Progenics Pharmaceutical, Janssen Research & Development, Astellas, CoImmune; Non-Financial Interests, Leadership Role, Past President: SUO-CTC; Non-Financial Interests, Officer, President-elect: Northeastern Section of AUA; Non-Financial Interests, Leadership Role, Deputy Director: Upstate Cancer Center. M. Vasanawala: Other, Personal, Local PI: Lantheus; Other, Institutional, Research Grant: Lantheus. G.A. Ulaner: Other, Personal, Speaker, Consultant, Advisor: Lantheus, GE Healthcare; Other, Personal, Advisory Board: Precirix, Nuclidium. F. Pouliot: Other, Personal, Speaker, Consultant, Advisor: AbbVie, Advanced Accelator Applications/Novartis, Amgen, Astellas Pharma, AstraZeneca, Bayer, Janssen, Merck, Sanofi, TerSera, Tolmar. D. Laidley: Other, Personal, Advisory Board: Advanced Accelerator Application/Novartis, Bayer, Ipsen; Other, Personal, Local PI: Advanced Accelerator Applications/Novartis, POINT Biopharma, Progenics; Other, Personal, Speaker, Consultant, Advisor: Advanced Accelerator Applications/ Novartis. N. Fleshner: Other, Personal, Local PI: Lantheus; Other, Institutional, Research Grant: Lantheus. F. Saad: Financial Interests, Personal, Advisory Board: Astellas, Bayer, BMS, Janssen, Pfizer, Myovant, Novartis, AstraZeneca, Merck; Financial Interests, Institutional, Local PI: Novartis, Astellas, Bayer, Janssen, Sanofi, BMS, Amgen, Pfizer, Merck; Financial Interests, Institutional, Coordinating PI: AstraZeneca. Y. Menda: Other, Institutional, Research Funding: Novartis, Perspective Therapeutics, Fusion Pharmaceuticals, Progenics Pharmaceuticals.
Resources from the same session
1553P - Access to EMA approved drugs in Europe, disparities across a border
Presenter: Orla Fitzpatrick
Session: Poster session 10
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10